免疫原性
病毒学
鼻腔给药
免疫
接种疫苗
病毒
医学
新城疫
效价
抗体
免疫学
作者
Qiu‐Yan Zhang,Hongqing Zhang,Yanan Zhang,Zherui Zhang,Xiaodan Li,Mengchan Hao,Yang Zhang,Jiaqi Li,Yan-Yan Hu,Xiaoling Chen,Li Wang,Yu-Jia Shi,Cheng‐Lin Deng,Jianjun Chen,Han‐Qing Ye,Bo Zhang
标识
DOI:10.1016/j.antiviral.2023.105757
摘要
Despite global vaccination efforts, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve and spread globally. Currently, the development of affordable vaccine against Omicron variant of concern (VOC) is necessary. Here, we assessed the safety and immunogenicity of a SARS-CoV-2 vaccine consisting of a live Newcastle disease virus vector expressing the spike (S) protein of Omicron BA.1 administrated intranasally (IN) or intramuscularly (IM) in Golden Syrian hamster model. Immunogenicity studies showed that the prime-boost regimen elicited high antibody titers and the modified S antigen (Sm-F) could induce robust antibody response in low dosage immunization through IN route. Sera of the immunized hamsters provided effective cross-neutralizing activity against different Omicron variants, the prototype and delta strains of SARS-CoV-2. Moreover, the vaccine could provide complete immunoprotection in hamsters against the Omicron BA.1 challenge by either intranasal or intramuscular immunization. Overall, our study provides an alternative nasal vaccine against the SARS-CoV-2 Omicron variants.
科研通智能强力驱动
Strongly Powered by AbleSci AI